Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial

Bär, Sarah; Kavaliauskaite, Raminta; Otsuka, Tatsuhiko; Ueki, Yasushi; Häner, Jonas; C.M. Siontis, George; Stortecky, Stefan; Shibutani, Hiroki; Temperli, Fabrice; Kaiser, Christoph; F. Iglesias, Juan; van Geuns, Robert‐Jan; Daemen, Joost; Spirk, David; Engstrøm, Thomas; Lang, Iréne; Windecker, Stephan; C. Koskinas, Konstantinos; Losdat, Sylvain; Räber, Lorenz

doi:10.4244/eij-d-23-00201

Public

Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial

Published in EuroIntervention • Jul 1, 2023

Authors:

Sarah Bär

Raminta Kavaliauskaite

Tatsuhiko Otsuka

Abstract

BACKGROUND: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on top of statins leads to plaque regression and stabilisation. The effects of PCSK9 inhibitors on coronary physiology and angiographic diameter stenosis (DS%) are unknown. AIMS: This study aimed to investiga...

Subject

Alirocumab

Medicine

Cardiology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!